PXL770

A Potential Breakthrough Therapy for Metabolic Disorders and Type 2 Diabetes

PXL770 directly activates adenosine monophosphate-activated protein kinase (AMPK), an enzyme that controls whole-body energy metabolism and plays an important role in metabolic diseases and the management of diabetes. Compounds that directly target AMP kinase normalize glycemia and lipid profiles by:

  • Increasing glucose uptake independently of insulin
  • Increasing lipid oxidation
  • Decreasing glucose and lipid production, restoring energy balance

In addition to its anti-diabetic properties, PXL770 has the potential to treat lipid-related abnormalities (cholesterol, triglycerides), which are present in a vast majority of diabetic patients and are the cause of cardiovascular incidents among this population (65% of deaths among diabetics are due to cardiovascular events*).

* Source: Centers for Disease Control (CDC): www.cdc.gov

Benefits: Targeting Cardiovascular Risk Factors

We observed several benefits on metabolic parameters in various animal models such as improved glucose and lipid profiles, as well as a benefit on weight. Other benefits include:

  • A dose dependent A1c reduction
  • A dose dependent benefit on weight
  • A dose dependent plasma triglycerides reduction
  • A dose dependent liver triglycerides reduction

Clinical Trials

PXL770 is in Phase 1.

Phase 1

PXL770 will be tested for safety, tolerability and pharmacokinetics

Trials

  • Metabolite identification and qualification
  • Safety, tolerability and pharmacokinetics after single and multiple ascending doses

Phase 2a

PXL770 has the potential to be studied in several metabolic disorders, including liver and kidney diseases, as well as type 2 diabetes in a proof-of-concept program.  

Trials

  • Glycemic parameters (FPG, OGTT)
  • Other cardiovascular risks: lipids, weight, inflammation
  • Safety in target population
  • AMPK biomarker in type 2 diabetes patients

Our Development and Commercialization Strategy

PXL770, as a first-in-class novel mechanism, provides a unique opportunity for patients with metabolic disorders and type 2 diabetes with high cardiovascular risk. Our Phase 1 trial will assess safety, tolerability and pharmacokinetics.